Methods for reducing exacerbation rates of asthma using benralizumab

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9441037
SERIAL NO

14453942

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Provided herein is are methods of reducing exacerbations of asthma in an asthma patient, comprising administering to the patient an effective amount of the anti-interleukin-5 receptor (IL-5R) antibody benralizumab or an antigen-binding fragment thereof.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • ASTRAZENECA AB

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Raible, Donald Berwyn, US 8 113
Roskos, Lorin Gaithersburg, US 21 58
Wang, Bing Gaithersburg, US 375 3261
Ward, Christine Gaithersburg, US 10 11

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Mar 13, 2024
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 13, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00